Primary Antibiotic Prophylaxis Using Co-trimoxazole to Prevent Spontaneous Bacterial Peritonitis in Cirrhosis

  • STATUS
    Recruiting
  • participants needed
    548
  • sponsor
    University College, London
Updated on 19 February 2024
antibiotics
cirrhosis
spontaneous bacterial peritonitis
ascites
polymorphonuclear count
microbial culture

Summary

A multicentre, interventional, double-blind, placebo-controlled, parallel-arm, phase 3, randomised controlled trial to evaluate the use of co-trimoxazole as primary prophylaxis for spontaneous bacterial peritonitis

Details
Condition Spontaneous Bacterial Peritonitis
Age 18years - 100years
Treatment Placebo Oral Tablet, Co-Trimoxazole 960Mg Dispersible Tablet
Clinical Study IdentifierNCT04395365
SponsorUniversity College, London
Last Modified on19 February 2024

Eligibility

Yes No Not Sure

Inclusion Criteria

Patients with liver cirrhosis and ascites with ascitic fluid protein count <2.0 g/dL (from sample taken within <12 weeks prior to randomisation)
Patients with ascitic polymorphonuclear count <250 cells/mm3 and negative microbial culture at 5 days (on the last sample sent within <12 weeks prior to randomisation)
Patient at least 18 years of age
Documented informed consent to participate

Exclusion Criteria

Patients with previous Spontaneous Bacterial Peritonitis (SBP)
Patients receiving palliative care with an expected life expectancy of <8 weeks
Allergic to co-trimoxazole, trimethoprim or sulphonamides
Pregnant or lactating mothers
Patient enrolled in a clinical trial of investigational medicinal products (IMPs) that would impact on their participation in the study
Patients with persistent hyperkalaemia (>6.5 mmol/L) related to pre-existing kidney disease with reduction not possible
Patients receiving antibiotic prophylaxis (except for rifaximin)
Patients with long-term ascites drains
Women of child bearing potential and males with a partner of child bearing potential without effective contraception for the duration of trial treatment
Patients with pathological blood count changes (granulocytopenia, megaloblastic anaemia)
Severe thrombocytopenia with a platelet count <30 x109 /L
Patients with severe renal impairment, with eGFR <15 ml/min
Patients with skin conditions: exudative erythema multiform, Stevens-Johnson syndrome, toxic epidermal necrolysis and drug eruption with eosinophilia and systemic symptoms
Patients with congenital conditions: congenital glucose-6-Phosphate dehydrogenase deficiency of the erythrocytes, haemoglobin anomalies such as Hb Kln and Hb Zrich
Patients with acute porphyria
Any clinical condition which the investigator considers would make the patient unsuitable for the trial
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

Study AnnotationsStudy Notes

Notes added here are public and can be viewed by anyone. Notes added here are only available to you and those who you share with.

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.